comprehensive -WSS

comprehensive

author：focus 2025-09-27 11:09:20 Page View：448

Adam's take main illustration — Molly Ferguson/STAT

I am one week away from the launch of my weekly email newsletter! It’s called Adam’s Biotech Scorecard, and it’s exclusively for STAT subscribers. One catch: We need you to sign up, which you can do here. What should you expect to see in my newsletter each week? Unfiltered, uncompromising, and (hopefully) valuable insight and analysis from the intersection of Wall Street and biotech. Plus, a few dashes of fun.

Do you have a biotech-related question you want me to answer in the newsletter? Send me an email at [email protected].

This week: A preview of Intra-Cellular Therapies’ Phase 3 study in major depressive disorder, and a couple of liver-disease physician perspectives on Rezdiffra, the newly approved treatment for MASH from Madrigal Pharmaceuticals.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Masked men burn a market in a Mexican city plagued by gang violence, killing 9 people
Next article： Supreme Court strikes down use of affirmative action

focus

Sports medicine is finally prioritizing gender equality

MollyFergusonforSTATWhencyclistAlisonTetrickjoinedthesport’sprofessionalranks,shereceivedtheperkstha

ALS groups 'won't be played again' by the FDA, drug sponsors

MattScozzariholdshisgirlfriendSabrinaParker'shandduringafriendshipceremonyinJacksonville,N.C.,inNove

Dobbs anniversary: the lost opportunity of abortion as health care

NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

How to address the problem of discarded donor organs

Adoctorflushesadonorkidneyduringatransplantprocedure.BRENDANSMIALOWSKI/AFP/GettyImagesAsIwasgettingr